In the biotechnology industry, companies must define and focus on their target market. While the market may evolve over time, understanding the current target market is critical for shaping the technology innovation strategy.
Failure to identify the target market early on can lead to developing highly sophisticated solutions that ultimately solve no one's problems. Focusing on the right target market enables companies to develop effective solutions with real-world applications.
This concept is discussed in greater detail in an episode of the Smart Biotech Scientist Podcast with James Ryall who empowers biomanufacturing startups to reach the market faster, hosted by David Brühlmann, founder of Brühlmann Consulting.
The Journey of James Ryall in Biotech
Academic Roots and Early Research
James Ryall's journey into biomanufacturing and regenerative medicine began at the University of Melbourne, where he pursued a PhD focused on age-related muscle wasting and weakness.
His academic interest in skeletal muscle was driven by his interest in physical activity and his scientific curiosity about how muscle tissue changes as we age. Through his PhD research, he became deeply familiar with the molecular pathways that regulate muscle size and strength and how they are affected by aging.
Transitioning to Regenerative Medicine
Following his PhD, James Ryall's research at the University of Melbourne continued to explore regenerative medicine, specifically focusing on muscle damage and repair cycles.
This research led him to pursue work with Vittorio Satarelli at the National Institutes of Health in the United States, where he spent five years investigating muscle stem cells, their transcriptome, and how the metabolic environment influences their growth.
Exploring the Cultured Meat Industry
James Ryall's experience in regenerative medicine led to an intriguing discovery: he was growing meat in a dish by growing muscle stem cells. This realization marked his entry into the cultured meat industry.
As the cultivated meat movement gained traction, James Ryall became a vocal advocate for its potential and began speaking publicly about the development of cultured meats, including Beyond Meat and other cell-based meat innovations. His involvement in this space eventually led to an opportunity with Vow, a cultured meat company.
Joining Vow and Advancing Bio-Manufacturing
In 2019, after extensive public discussions about cultured meat, Tim Noakesmith and George Peppou, the co-founders of Vow, an Australian cultured meat company, approached James Ryall.
Initially hesitant to leave his academic role, James Ryall eventually joined Vow as Chief Scientist. During his four years with the company, James Ryall contributed to developing bio-manufactured meat products that were ultimately brought to market in Singapore.
This experience allowed him to scale muscle cell production at an unprecedented level, moving from academic research to industrial-scale bio-manufacturing.
Transitioning to Consulting
The Move to Consulting
After his time at Vow, James Ryall took a brief hiatus to regroup before transitioning into consulting. His goal was to continue working with innovative companies and technologies that had the potential to address some of the world's most pressing challenges.
Through consulting, James Ryall found an opportunity to help biotech founders accelerate their businesses, avoid common pitfalls, and align technical strategies with commercial goals.
Challenges in Consulting
The consulting field presents unique challenges. For James Ryall, one of the most notable learning experiences was realizing the importance of articulating his value proposition clearly.
Early in his consulting career, James Ryall struggled to communicate how his expertise could benefit clients. This experience highlighted the need for clarity in consulting and business development, an important lesson for entrepreneurs and consultants alike.
How James Ryall Helps Biotech Startups
Working with Pre-Seed to Series B Companies
James Ryall specializes in helping companies from pre-seed to Series B stages, particularly those focused on bio-manufacturing for non-clinical products.
His consulting process emphasizes aligning technical strategies with clear commercial outcomes. This alignment is crucial for reducing time-to-market and ensuring the company focuses on achievable, impactful goals.
Defining Market and Value Proposition
A key part of James Ryall's process involves helping companies define their target market and unique value proposition. In his initial discussions with new clients, James Ryall focuses on understanding the company's market target and how it differentiates its product or technology.
This exercise is foundational to setting up a technical strategy that aligns with market needs and business objectives.
If you're doing a lot of technical work without understanding who your market is to begin with, you run the risk of developing a just a beautiful technical solution to a problem that no one has.
Navigating Market Opportunities and Company Pivots
Consulting with biotech startups often involves guiding them through market shifts or product pivots. James Ryall recounted a recent experience in which a company realized its target market was much smaller than anticipated.
By pivoting to a new market, the company avoided six months of unnecessary work and began targeting a more promising opportunity. This example illustrates the importance of ongoing market evaluation and strategic flexibility in biotech startups.
The Importance of Articulating Value Proposition
The Role of Scientists as Salespeople
An important takeaway from James Ryall's experience is the need for biotech professionals, whether consultants, researchers, or technical founders, to clearly articulate their value proposition. This skill is vital for selling products and gaining buy-in from peers, investors, and collaborators. Presenting a compelling case for the value of one's work is essential in moving projects forward.
Evolving Personal Value Propositions
James Ryall acknowledged that his value proposition continues to evolve even as a consultant. As he gains more experience, he refines his messaging to ensure that he effectively communicates the results he can deliver for his clients. This iterative process, he believes, is key to staying aligned with client needs and market realities.
Building Trust and Accountability in Teams
The Importance of Ownership and Accountability
James Ryall's consulting approach emphasizes trust and transparency in building teams focused on high levels of ownership and accountability. He has found that teams lacking strong ownership often struggle to move quickly and efficiently, hindering progress and innovation.
By fostering a culture of responsibility, James Ryall helps teams overcome obstacles and move towards their goals with agility.
Fractional Consulting and Working Out of a Job
James Ryall's consulting model includes fractional work, where he contributes to a company part-time, typically one day a week or every two weeks. The goal is for James Ryall to set up systems and frameworks that allow the team to continue working effectively after his involvement ends.
This model of working to "work himself out of a job" ensures that his impact is long-lasting and sustainable, allowing the company to grow independently once initial challenges are addressed.
The Challenges of Scaling and Regulatory Processes
One of the biggest hurdles biotech startups face is managing the complexities of scaling and navigating the regulatory environment. James Ryall emphasizes that scaling up and engaging with regulatory bodies early on are critical steps for companies looking to bring products to market.
Scaling Early
Scaling is often delayed because startups focus on optimizing their benchtop processes.
However, James Ryall warns that optimizing a benchtop process does not directly translate to success when scaling to larger systems. He suggests that companies should begin scaling sooner than they might be ready.
Delaying scaling can result in significant inefficiencies and wasted resources.
Navigating Regulatory Challenges
Another common pitfall is underestimating the length and complexity of regulatory processes. Whether a product is intended for food or therapeutic use, engaging with regulatory agencies such as the FDA (Food and Drug Administration) or FSANZ (Food Standards Australia and New Zealand) early is crucial.
Companies often find themselves unprepared for the time it takes to receive regulatory approval, especially when they only have a short runway before launching their product. James Ryall advises startups to initiate discussions with regulatory bodies well ahead of time to avoid these challenges.
Scaling and regulations. They are by far and away the two biggest challenges that often get left too late. If you are a biomanufacturing clinical or not, if you're a biomanufacturing that startup or company and you have optimized your benchtop scale to the point that it's perfect, you've waited too late, you needed to and you need to move into a scaled up process well before your benchtop process is optimized. Because all that time that you spend optimizing your benchtop process, not much of that is going to translate into your scaled up process. You need to find a way to start scaling sooner than you think you're ready for.
The Importance of Education and Sharing Experiences
James Ryall highlights that one of the best ways to overcome the challenges of scaling and regulations is through education and sharing experiences. Industry professionals should collaborate, participate in discussions, and learn from one another's successes and failures.
He believes that resources such as podcasts, like the one he participated in, provide an excellent platform for sharing knowledge and improving understanding of biomanufacturing.
Emerging Trends in Biomanufacturing
The biomanufacturing industry is poised for transformative change, with new opportunities emerging as biological production techniques advance. James Ryall is excited about the potential of bio-based products, which he compares to the early days of the software engineering revolution in the 1990s.
The Role of Biology in Manufacturing
James Ryall stresses the immense potential of biology as a manufacturing tool.
According to the McKinsey Biorevolution report, up to 60% of consumer goods could be replaced by bio-based equivalents. This includes fuel, specialty chemicals, soaps, textiles, and even human breast milk. As James Ryall puts it, the cell is the most advanced manufacturing facility in the world, capable of producing a wide array of bio-based products.
Cultured Meat and the Future of Food
James Ryall is particularly interested in cultured meat, a key area within biomanufacturing. He believes that cultured food will become widely available worldwide, though it is important to note that many companies in the field may not succeed in bringing products to market. Nonetheless, James Ryall is optimistic about the overall industry's success.
He draws an interesting comparison to Tesla, noting that successful bio-manufacturing will not simply replicate existing products but aim to make new, better products. For example, cultured meat is not just about recreating a traditional chicken breast or steak; it's about creating something that surpasses the original in terms of taste, nutrition, and sustainability.
Price and Consumer Acceptance
Price remains a key factor in widespread adoption. While sustainability and animal ethics are important to a small portion of the population, most consumers prioritize taste, nutrition, and price when purchasing food products. James Ryall believes that for cultured meat to become mainstream, it must meet these consumer expectations while offering a compelling value proposition.
Staying Ahead in a Rapidly Evolving Industry
Given the fast pace of innovation in biomanufacturing, staying ahead of trends is no easy task.
James Ryall admits that it is impossible to stay on top of everything, considering the broad scope of biomanufacturing, which includes cell-based cultivation, fermentation, molecular farming, and cell-free processes.
However, he stays informed by regularly reading industry reports, engaging with venture capital updates, and speaking with founders in the field. These conversations provide valuable insights into emerging technologies and challenges, offering a more comprehensive understanding of what is happening across the sector.
Key Takeaways for Industry Professionals
James Ryall offers several key takeaways for both seasoned professionals and newcomers to the biomanufacturing space:
- For experienced bioprocessing professionals: A significant opportunity exists to contribute to the non-clinical biomanufacturing sector. Many startups need individuals with expertise in optimizing bioprocessing lines, and this knowledge can help fuel the growth of biomanufacturing.
- For early-stage companies: It is essential to think about scaling up early. Whether working with shaker flasks or other small-scale equipment, companies should continuously consider how they can move to larger-scale production. The learning process during scaling will be invaluable for optimizing processes and developing more efficient systems.
Final Remarks
In conclusion, the discussion with James Ryall provided invaluable insights into the challenges and opportunities within the biomanufacturing sector.
We explored the complexities of bioprocessing, emphasizing the importance of scaling up early and engaging with regulatory bodies to avoid costly delays. We also highlighted the need for education and knowledge sharing to help startups navigate these challenges. James Ryall elaborated on the exciting potential of biomanufacturing, from bio-based products to cultured meat, underscoring the importance of creating superior products that meet consumer tastes, nutrition, and price demands.
By staying informed, scaling early, and embracing innovation, biomanufacturing professionals can contribute to shaping the future of biotechnology.
About James Ryall
James Ryall is a distinguished strategic consultant with over twenty years of expertise in cell biology, biomanufacturing, and regenerative medicine. After an illustrious academic career at The University of Melbourne and the National Institutes of Health, James transitioned to the biomanufacturing sector, serving as the Chief Scientific Officer at Vow, where he spearheaded cultured meat innovations.
Equipped with a profound understanding of science and business, he now advises a diverse array of biotech companies employing biomanufacturing technologies to tackle some of today's most pressing challenges. His mission is to collaborate with visionary biotech founders, from pre-seed to Series B+, to accelerate the journey of world-changing products to market.
Connect with James Ryall on LinkedIn.
David Brühlmann is a strategic advisor who helps C-level biotech leaders reduce development and manufacturing costs to make life-saving therapies accessible to more patients worldwide.
He is also a biotech technology innovation coach, technology transfer leader, and host of the Smart Biotech Scientist podcast—the go-to podcast for biotech scientists who want to master biopharma CMC development and biomanufacturing.
Hear It From The Horse’s Mouth
Want to listen to the full interview? Go to Smart Biotech Scientist Podcast.
Want to hear more? Do visit the podcast page and check out other episodes.
Do you wish to simplify your biologics drug development project? Contact Us
